An Open-label, Multicenter, Efficacy and Safety Pilot Study of 6-month Canakinumab Treatment With up to 6-month Follow-up in Patients With Active Hyper-IgD Syndrome (HIDS)

Trial Profile

An Open-label, Multicenter, Efficacy and Safety Pilot Study of 6-month Canakinumab Treatment With up to 6-month Follow-up in Patients With Active Hyper-IgD Syndrome (HIDS)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Hereditary autoinflammatory diseases; Hyperimmunoglobulinaemia
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 08 May 2017 Primary endpoint (Number of Flares Per Participant During Historical Period and Treatment Period) has been met.
    • 08 May 2017 Results published in the Arthritis and Rheumatology
    • 18 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top